{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T03:44:34Z","timestamp":1777866274069,"version":"3.51.4"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"am","delay-in-days":341,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015691","name":"National Institute of Allergy and Infectious Diseases Division of Microbiology and Infectious Diseases","doi-asserted-by":"publisher","award":["HHS-N272201400053C"],"award-info":[{"award-number":["HHS-N272201400053C"]}],"id":[{"id":"10.13039\/100015691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.vaccine.2025.126744","type":"journal-article","created":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T23:00:40Z","timestamp":1738710040000},"page":"126744","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Immunogenicity and safety study of a single dose of SpikoGen\u00ae vaccine as a heterologous or homologous intramuscular booster following a primary course of mRNA, adenoviral vector or recombinant protein COVID-19 vaccine in ambulatory adults"],"prefix":"10.1016","volume":"49","author":[{"given":"Yoshikazu","family":"Honda-Okubo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitar","family":"Sajkov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce","family":"Wauchope","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph V.","family":"Turner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brendan","family":"Vote","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Antipov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Greiciely","family":"Andr\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuri","family":"Lebedin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikolai","family":"Petrovsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2025.126744_bb0005","article-title":"WHO declares end to COVID-19\u2019s emergency phase","author":"Lenharo","year":"2023","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.vaccine.2025.126744_bb0010","doi-asserted-by":"crossref","first-page":"8078","DOI":"10.1038\/s41467-023-43703-3","article-title":"Evolution and neutralization escape of the SARS-CoV-2 BA.2.86 subvariant","volume":"14","author":"Khan","year":"2023","journal-title":"Nat Commun"},{"issue":"3","key":"10.1016\/j.vaccine.2025.126744_bb0015","doi-asserted-by":"crossref","first-page":"590","DOI":"10.3201\/eid2903.221546","article-title":"Seroprevalence of specific SARS-CoV-2 antibodies during omicron BA.5 wave, Portugal, April-June 2022","volume":"29","author":"Kislaya","year":"2023","journal-title":"Emerg Infect Dis"},{"issue":"10328","key":"10.1016\/j.vaccine.2025.126744_bb0020","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S0140-6736(22)00152-0","article-title":"Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression","volume":"399","author":"Feikin","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2025.126744_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.101010","article-title":"Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18 years or older: a randomized, double-blind, placebo-controlled, phase 1\/2 trial","volume":"38","author":"Guo","year":"2021","journal-title":"EClinicalMedicine"},{"issue":"17","key":"10.1016\/j.vaccine.2025.126744_bb0030","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMc2113468","article-title":"SARS-CoV-2 neutralization with BNT162b2 vaccine dose 3","volume":"385","author":"Falsey","year":"2021","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.vaccine.2025.126744_bb0035","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S2213-2600(21)00357-X","article-title":"Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study","volume":"9","author":"Hillus","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"1","key":"10.1016\/j.vaccine.2025.126744_bb0040","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/s41422-021-00590-x","article-title":"Recombinant protein subunit vaccine booster following two-dose inactivated vaccines dramatically enhanced anti-RBD responses and neutralizing titers against SARS-CoV-2 and variants of concern","volume":"32","author":"Ai","year":"2022","journal-title":"Cell Res"},{"issue":"11","key":"10.1016\/j.vaccine.2025.126744_bb0045","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1056\/NEJMra2206573","article-title":"Covid-19 vaccines - immunity, variants, boosters","volume":"387","author":"Barouch","year":"2022","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.vaccine.2025.126744_bb0050","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1038\/s41577-021-00642-8","article-title":"Lessons from vaccine-induced immune thrombotic thrombocytopenia","volume":"21","author":"Kelton","year":"2021","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2025.126744_bb0055","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/s41541-024-00893-1","article-title":"Myocarditis associated with COVID-19 vaccination","volume":"9","author":"Buoninfante","year":"2024","journal-title":"NPJ Vaccines"},{"issue":"83","key":"10.1016\/j.vaccine.2025.126744_bb0060","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.adh3455","article-title":"Cytokinopathy with aberrant cytotoxic lymphocytes and profibrotic myeloid response in SARS-CoV-2 mRNA vaccine-associated myocarditis","volume":"8","author":"Barmada","year":"2023","journal-title":"Sci Immunol"},{"issue":"12","key":"10.1016\/j.vaccine.2025.126744_bb0065","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1097\/INF.0000000000004488","article-title":"Delayed induction of noninflammatory SARS-CoV-2 spike-specific IgG4 antibodies detected 1 year after BNT162b2 vaccination in children","volume":"43","author":"Kobbe","year":"2024","journal-title":"Pediatr Infect Dis J"},{"issue":"1","key":"10.1016\/j.vaccine.2025.126744_bb0070","doi-asserted-by":"crossref","first-page":"2363016","DOI":"10.1080\/21645515.2024.2363016","article-title":"Clinical development of SpikoGen(R), an Advax-CpG55.2 adjuvanted recombinant spike protein vaccine","volume":"20","author":"Petrovsky","year":"2024","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2025.126744_bb0075","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2022.927306","article-title":"A comprehensive review of the protein subunit vaccines against COVID-19","volume":"13","author":"Heidary","year":"2022","journal-title":"Front Microbiol"},{"issue":"36","key":"10.1016\/j.vaccine.2025.126744_bb0080","doi-asserted-by":"crossref","first-page":"5407","DOI":"10.1016\/j.vaccine.2012.06.009","article-title":"Randomized clinical trial of immunogenicity and safety of a recombinant H1N1\/2009 pandemic influenza vaccine containing Advax\u2122 polysaccharide adjuvant","volume":"30","author":"Gordon","year":"2012","journal-title":"Vaccine"},{"issue":"23","key":"10.1016\/j.vaccine.2025.126744_bb0085","doi-asserted-by":"crossref","first-page":"3182","DOI":"10.1016\/j.vaccine.2022.04.041","article-title":"Covax-19\/Spikogen(R) vaccine based on recombinant spike protein extracellular domain with Advax-CpG55.2 adjuvant provides single dose protection against SARS-CoV-2 infection in hamsters","volume":"40","author":"Li","year":"2022","journal-title":"Vaccine"},{"issue":"40","key":"10.1016\/j.vaccine.2025.126744_bb0090","doi-asserted-by":"crossref","first-page":"5940","DOI":"10.1016\/j.vaccine.2021.07.087","article-title":"Immunisation of ferrets and mice with recombinant SARS-CoV-2 spike protein formulated with Advax-SM adjuvant protects against COVID-19 infection","volume":"39","author":"Li","year":"2021","journal-title":"Vaccine"},{"issue":"32","key":"10.1016\/j.vaccine.2025.126744_bb0095","doi-asserted-by":"crossref","first-page":"4710","DOI":"10.1016\/j.vaccine.2023.06.063","article-title":"An Advax-CpG55.2 adjuvanted recombinant spike protein vaccine protects cynomolgus macaques from a homologous SARS-CoV-2 virus challenge","volume":"41","author":"Honda-Okubo","year":"2023","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2025.126744_bb0100","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1016\/j.vaccine.2024.01.034","article-title":"Study of immunogenicity and efficacy against omicron BA.5 of recombinant protein-based COVID-19 vaccine delivered by intramuscular and mucosal routes in nonhuman primates","volume":"42","author":"Pal","year":"2024","journal-title":"Vaccine"},{"issue":"48","key":"10.1016\/j.vaccine.2025.126744_bb0105","doi-asserted-by":"crossref","first-page":"7116","DOI":"10.1016\/j.vaccine.2023.10.018","article-title":"Advax-CpG55.2-adjuvanted monovalent or trivalent SARS-CoV-2 recombinant spike protein vaccine protects hamsters against heterologous infection with Beta or Delta variants","volume":"41","author":"Honda-Okubo","year":"2023","journal-title":"Vaccine"},{"issue":"40","key":"10.1016\/j.vaccine.2025.126744_bb0110","doi-asserted-by":"crossref","first-page":"5940","DOI":"10.1016\/j.vaccine.2021.07.087","article-title":"Immunisation of ferrets and mice with recombinant SARS-CoV-2 spike protein formulated with Advax-SM adjuvant protects against COVID-19 infection","volume":"39","author":"Li","year":"2021","journal-title":"Vaccine"},{"issue":"9","key":"10.1016\/j.vaccine.2025.126744_bb0115","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.cmi.2022.04.004","article-title":"Safety and immunogenicity of SpikoGen(R), an advax-cpg55.2-adjuvanted sars-cov-2 spike protein vaccine: a phase 2 randomized placebo-controlled trial in both seropositive and seronegative populations","volume":"28","author":"Tabarsi","year":"2022","journal-title":"Clin Microbiol Infect"},{"issue":"2","key":"10.1016\/j.vaccine.2025.126744_bb0120","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/imm.13661","article-title":"Ability of SpikoGen(R), an Advax-CpG adjuvanted recombinant spike protein vaccine, to induce cross-neutralising antibodies against SARS-CoV-2 variants","volume":"170","author":"Honda-Okubo","year":"2023","journal-title":"Immunology"},{"issue":"2","key":"10.1016\/j.vaccine.2025.126744_bb0125","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.cmi.2022.09.001","article-title":"Evaluating the efficacy and safety of SpikoGen(R), an Advax-CpG55.2-adjuvanted severe acute respiratory syndrome coronavirus 2 spike protein vaccine: a phase 3 randomized placebo-controlled trial","volume":"29","author":"Tabarsi","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.vaccine.2025.126744_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.111436","article-title":"Comparative immunogenicity and safety of SpikoGen(R), a recombinant SARS-CoV-2 spike protein vaccine in children and young adults: an immuno-bridging clinical trial","volume":"127","author":"Tabarsi","year":"2024","journal-title":"Int Immunopharmacol"},{"issue":"3","key":"10.1016\/j.vaccine.2025.126744_bb0135","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/imm.13540","article-title":"Immunogenicity and safety of SpikoGen(R), an adjuvanted recombinant SARS-CoV-2 spike protein vaccine as a homologous and heterologous booster vaccination: a randomized placebo-controlled trial","volume":"167","author":"Tabarsi","year":"2022","journal-title":"Immunology"},{"issue":"12","key":"10.1016\/j.vaccine.2025.126744_bb0140","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1080\/21645515.2018.1502517","article-title":"A post hoc analysis utilizing the FDA toxicity grading scale to assess injection site adverse events following immunization with the live attenuated zoster vaccine (ZVL)","volume":"14","author":"Popmihajlov","year":"2018","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2025.126744_bb0145","article-title":"Influence of age on the effectiveness and duration of protection of Vaxzevria and CoronaVac vaccines: a population-based study","volume":"6","author":"Cerqueira-Silva","year":"2022","journal-title":"Lancet Reg Health Am"},{"issue":"7","key":"10.1016\/j.vaccine.2025.126744_bb0150","doi-asserted-by":"crossref","first-page":"11180","DOI":"10.1021\/acsnano.1c03972","article-title":"Primary, recall, and decay kinetics of SARS-CoV-2 vaccine antibody responses","volume":"15","author":"Ibarrondo","year":"2021","journal-title":"ACS Nano"},{"issue":"1","key":"10.1016\/j.vaccine.2025.126744_bb0155","doi-asserted-by":"crossref","first-page":"4466","DOI":"10.1038\/s41467-022-32254-8","article-title":"Levels of SARS-CoV-2 antibodies among fully vaccinated individuals with Delta or omicron variant breakthrough infections","volume":"13","author":"Staerke","year":"2022","journal-title":"Nat Commun"},{"issue":"11","key":"10.1016\/j.vaccine.2025.126744_bb0160","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1038\/s41591-020-1083-1","article-title":"Seasonal coronavirus protective immunity is short-lasting","volume":"26","author":"Edridge","year":"2020","journal-title":"Nat Med"},{"issue":"14","key":"10.1016\/j.vaccine.2025.126744_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2022.06.005","article-title":"Antibody escape of SARS-CoV-2 omicron BA.4 and BA.5 from vaccine and BA.1 serum","volume":"185","author":"Tuekprakhon","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2025.126744_bb0170","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.bbrc.2021.07.062","article-title":"A non-RBM targeted RBD specific antibody neutralizes SARS-CoV-2 inducing S1 shedding","volume":"571","author":"Long","year":"2021","journal-title":"Biochem Biophys Res Commun"},{"issue":"6","key":"10.1016\/j.vaccine.2025.126744_bb0175","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/s41422-021-00490-0","article-title":"Structural basis for the different states of the spike protein of SARS-CoV-2 in complex with ACE2","volume":"31","author":"Yan","year":"2021","journal-title":"Cell Res"},{"issue":"6","key":"10.1016\/j.vaccine.2025.126744_bb0180","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1002\/rmv.405","article-title":"Antibody-dependent enhancement of viral infection: molecular mechanisms and in vivo implications","volume":"13","author":"Takada","year":"2003","journal-title":"Rev Med Virol"},{"issue":"10","key":"10.1016\/j.vaccine.2025.126744_bb0185","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1038\/s41564-020-00789-5","article-title":"Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies","volume":"5","author":"Lee","year":"2020","journal-title":"Nat Microbiol"},{"issue":"9","key":"10.1016\/j.vaccine.2025.126744_bb0190","doi-asserted-by":"crossref","DOI":"10.3390\/pathogens12091108","article-title":"In vitro antibody-dependent enhancement of SARS-CoV-2 infection could be abolished by adding human IgG","volume":"12","author":"Wang","year":"2023","journal-title":"Pathogens"},{"issue":"10","key":"10.1016\/j.vaccine.2025.126744_bb0195","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.2174\/138945007782151360","article-title":"Protein N-glycosylation in the baculovirus-insect cell system","volume":"8","author":"Shi","year":"2007","journal-title":"Curr Drug Targets"},{"issue":"7","key":"10.1016\/j.vaccine.2025.126744_bb0200","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01403-18","article-title":"Antigenicity and immunogenicity of differentially glycosylated hepatitis C virus E2 envelope proteins expressed in mammalian and insect cells","volume":"93","author":"Urbanowicz","year":"2019","journal-title":"J Virol"},{"issue":"3","key":"10.1016\/j.vaccine.2025.126744_bb0205","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/s41577-022-00784-3","article-title":"Broadly neutralizing antibodies to SARS-CoV-2 and other human coronaviruses","volume":"23","author":"Chen","year":"2023","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"10.1016\/j.vaccine.2025.126744_bb0210","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.it.2019.01.005","article-title":"Role of IgG3 in infectious diseases","volume":"40","author":"Damelang","year":"2019","journal-title":"Trends Immunol"},{"issue":"16","key":"10.1016\/j.vaccine.2025.126744_bb0215","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1093\/cid\/ciaa344","article-title":"Antibody responses to SARS-CoV-2 in patients with novel coronavirus disease 2019","volume":"71","author":"Zhao","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2025.126744_bb0220","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1080\/22221751.2021.1953403","article-title":"Antibody titres decline 3-month post-vaccination with BNT162b2","volume":"10","author":"Favresse","year":"2021","journal-title":"Emerg Microbes Infect"},{"issue":"3","key":"10.1016\/j.vaccine.2025.126744_bb0225","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s10534-022-00458-6","article-title":"Molecular mimicry of the receptor-binding domain of the SARS-CoV-2 spike protein: from the interaction of spike-specific antibodies with transferrin and lactoferrin to the antiviral effects of human recombinant lactoferrin","volume":"36","author":"Sokolov","year":"2023","journal-title":"Biometals"},{"issue":"12","key":"10.1016\/j.vaccine.2025.126744_bb0230","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1038\/s41564-020-00813-8","article-title":"Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans","volume":"5","author":"Seow","year":"2020","journal-title":"Nat Microbiol"},{"issue":"7","key":"10.1016\/j.vaccine.2025.126744_bb0235","doi-asserted-by":"crossref","first-page":"255","DOI":"10.15585\/mmwr.mm7107e2","volume":"71","author":"Ferdinands","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2025.126744_bb0240","first-page":"10","article-title":"SARS-CoV-2 spike protein induces inflammation via TLR2-dependent activation of the NF-kappaB pathway","author":"Khan","year":"2021","journal-title":"Elife"},{"issue":"4","key":"10.1016\/j.vaccine.2025.126744_bb0245","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1021\/acschemneuro.2c00610","article-title":"SARS-CoV-2 spike protein downregulates cell surface alpha7nAChR through a helical motif in the spike neck","volume":"14","author":"Tillman","year":"2023","journal-title":"ACS Chem Neurosci"},{"issue":"10","key":"10.1016\/j.vaccine.2025.126744_bb0250","doi-asserted-by":"crossref","first-page":"6076","DOI":"10.1007\/s12035-022-02947-8","article-title":"A functional interaction between Y674-R685 region of the SARS-CoV-2 spike protein and the human alpha7 nicotinic receptor","volume":"59","author":"Chrestia","year":"2022","journal-title":"Mol Neurobiol"},{"issue":"6","key":"10.1016\/j.vaccine.2025.126744_bb0255","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.bpj.2021.01.037","article-title":"A potential interaction between the SARS-CoV-2 spike protein and nicotinic acetylcholine receptors","volume":"120","author":"Oliveira","year":"2021","journal-title":"Biophys J"},{"issue":"12","key":"10.1016\/j.vaccine.2025.126744_bb0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2021.166260","article-title":"SARS-CoV-2 spike promotes inflammation and apoptosis through autophagy by ROS-suppressed PI3K\/AKT\/mTOR signaling","volume":"1867","author":"Li","year":"2021","journal-title":"Biochim Biophys Acta Mol basis Dis"},{"issue":"13","key":"10.1016\/j.vaccine.2025.126744_bb0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109320","article-title":"Memory B cells targeting SARS-CoV-2 spike protein and their dependence on CD4(+) T cell help","volume":"35","author":"Pusnik","year":"2021","journal-title":"Cell Rep"},{"issue":"637","key":"10.1016\/j.vaccine.2025.126744_bb0270","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abn8057","article-title":"Neutralizing antibody responses elicited by SARS-CoV-2 mRNA vaccination wane over time and are boosted by breakthrough infection","volume":"14","author":"Evans","year":"2022","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.vaccine.2025.126744_bb0275","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.957107","article-title":"Mucosal immunity: the missing link in comprehending SARS-CoV-2 infection and transmission","volume":"13","author":"Russell","year":"2022","journal-title":"Front Immunol"},{"issue":"7","key":"10.1016\/j.vaccine.2025.126744_bb0280","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.chom.2021.05.010","article-title":"SARS-CoV-2 human T cell epitopes: Adaptive immune response against COVID-19","volume":"29","author":"Grifoni","year":"2021","journal-title":"Cell Host Microbe"},{"issue":"6","key":"10.1016\/j.vaccine.2025.126744_bb0285","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/s41591-020-0897-1","article-title":"Antibody responses to SARS-CoV-2 in patients with COVID-19","volume":"26","author":"Long","year":"2020","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.vaccine.2025.126744_bb0290","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/S1473-3099(22)00801-5","article-title":"Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression","volume":"23","author":"Bobrovitz","year":"2023","journal-title":"Lancet Infect Dis"},{"issue":"8","key":"10.1016\/j.vaccine.2025.126744_bb0295","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S1473-3099(24)00171-3","article-title":"The persistence of SARS-CoV-2 in tissues and its association with long COVID symptoms: a cross-sectional cohort study in China","volume":"24","author":"Zuo","year":"2024","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2025.126744_bb0300","doi-asserted-by":"crossref","first-page":"e487","DOI":"10.1093\/cid\/ciac722","article-title":"Persistent circulating severe acute respiratory syndrome coronavirus 2 spike is associated with post-acute coronavirus disease 2019 sequelae","volume":"76","author":"Swank","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2025.126744_bb0305","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.729251","article-title":"COVID-19 vaccine-related thrombosis: a systematic review and exploratory analysis","volume":"12","author":"Bilotta","year":"2021","journal-title":"Front Immunol"},{"issue":"51","key":"10.1016\/j.vaccine.2025.126744_bb0310","doi-asserted-by":"crossref","first-page":"7446","DOI":"10.1016\/j.vaccine.2021.10.075","article-title":"Novel adjuvants enhance immune responses elicited by a replication-defective human cytomegalovirus vaccine in nonhuman primates","volume":"39","author":"Li","year":"2021","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25000416?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25000416?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T08:21:15Z","timestamp":1777537275000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X25000416"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":62,"alternative-id":["S0264410X25000416"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.126744","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunogenicity and safety study of a single dose of SpikoGen\u00ae vaccine as a heterologous or homologous intramuscular booster following a primary course of mRNA, adenoviral vector or recombinant protein COVID-19 vaccine in ambulatory adults","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.126744","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"126744"}}